Boule Diagnostics AB (publ)
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clini… Read more
Boule Diagnostics AB (publ) (BDABF) - Total Assets
Latest total assets as of September 2024: $538.50 Million USD
Based on the latest financial reports, Boule Diagnostics AB (publ) (BDABF) holds total assets worth $538.50 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Boule Diagnostics AB (publ) - Total Assets Trend (2014–2023)
This chart illustrates how Boule Diagnostics AB (publ)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Boule Diagnostics AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2023)
Boule Diagnostics AB (publ)'s total assets of $538.50 Million consist of 37.1% current assets and 62.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.9% |
| Accounts Receivable | $153.87 Million | 20.4% |
| Inventory | $62.41 Million | 8.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $293.60 Million | 38.9% |
| Goodwill | $85.45 Million | 11.3% |
Asset Composition Trend (2014–2023)
This chart illustrates how Boule Diagnostics AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Boule Diagnostics AB (publ)'s current assets represent 37.1% of total assets in 2023, a decrease from 48.5% in 2014.
- Cash Position: Cash and equivalents constituted 4.9% of total assets in 2023, down from 8.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 25.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 38.9% of total assets.
Boule Diagnostics AB (publ) Competitors by Total Assets
Key competitors of Boule Diagnostics AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Boule Diagnostics AB (publ) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Boule Diagnostics AB (publ) generates 0.76x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Boule Diagnostics AB (publ) generates $ 3.31 in net profit.
Boule Diagnostics AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.04 | 1.37 | 1.34 |
| Quick Ratio | 0.77 | 1.04 | 1.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.20 Million | $ 83.70 Million | $ 57.49 Million |
Boule Diagnostics AB (publ) - Advanced Valuation Insights
This section examines the relationship between Boule Diagnostics AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.47 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | -0.6% |
| Total Assets | $755.11 Million |
| Market Capitalization | $223.94 Million USD |
Valuation Analysis
Below Book Valuation: The market values Boule Diagnostics AB (publ)'s assets below their book value (0.30 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Boule Diagnostics AB (publ)'s assets decreased by 0.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Boule Diagnostics AB (publ) (2014–2023)
The table below shows the annual total assets of Boule Diagnostics AB (publ) from 2014 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $755.11 Million | -0.64% |
| 2022-12-31 | $759.96 Million | +32.85% |
| 2021-12-31 | $572.03 Million | +19.24% |
| 2020-12-31 | $479.71 Million | -18.26% |
| 2019-12-31 | $586.87 Million | +17.17% |
| 2018-12-31 | $500.85 Million | +20.25% |
| 2017-12-31 | $416.49 Million | +14.32% |
| 2016-12-31 | $364.33 Million | +15.48% |
| 2015-12-31 | $315.48 Million | +12.69% |
| 2014-12-31 | $279.95 Million | -- |